COVID-19 UPDATES

October 12, 2020

For live updates on COVID-19 at the state level, county level and the Claremont neighborhood, you can check our COVID-19 Claremont Graduate University Dashboard.

- Global: Total confirmed cases: 37,594,267. Total deaths: 1,077,836. Total recoveries: 26,116,750.
- United States: Total confirmed cases: 7,768,629. Total deaths: 214,844. Total recoveries: 3,075,077.
- California: Total confirmed cases: 846,579. Total deaths: 16,564.
 - Virus transmission in Los Angeles County is rated as widespread by the governor's reopening regime, which places LA county in Tier 1 and keeps higher education and K-12 schools closed. Schools are permitted to open to stable groups of no more than 12 students with disabilities, students requiring instruction for English as a second language and students needing other specialized in-school services. Many businesses and services are allowed to reopen if performed outdoors with modifications. (Los Angeles Times)
 - Los Angeles County is still in the strictest level of the state's four-tier economicreopening roadmap. The county's recent testing positivity rate is low enough to qualify the county to move up to a less-restrictive tier, but the average daily number of new cases needs to drop to about 700 per day before any movement will occur. (NBC)

County-Level Statistics

Table 1. County-level confirmed cases, deaths, and case-fatality rates.

County	Confirmed Cases	Deaths	Case-fatality rate per 1,000	Total Population
Los Angeles	279909	6741	23.8	10,039,107
San Bernardino	57517	984	14.5	2,180,085
Orange	55345	1316	18.7	3,175,692
Ventura	13226	158	10.4	846,006
Riverside	61824	1256	18.9	2,470,546

Case-fatality rates may be biased due to undercounts in both cases and deaths

LA County

- Total of 279909 cases across LA County, including 6741 deaths.
- For the previous 24 hours, 15 new deaths and 1244 new cases.

Cities In Claremont's Neighborhood

Total number of cases: 12547

Table 2. Confirmed cases in Claremont and neighboring cities

Total Confirmed Cases	Total Population
408	36,478
512	32,206
5737	152,361
1341	39,437
3052	177,751
1497	77,000
	408 512 5737 1341 3052

Policy

- The world is experiencing a weak recovery from the COVID-19 recession.
 Governments have little choice but aggressive fiscal stimulus on top of already high public debt, juxtaposed against the risks of even greater and long-lasting scarring of economies in the absence of such stimulus. The global low interest rate environment will limit interest payment burdens, and, rather than crowding out private investment as in normal times, well-targeted government expenditures could serve as a catalyst for economic recovery. (Brookings)
- Regeneron has applied to the FDA for emergency use authorization for its experimental
 monoclonal antibody therapy for treating COVID-19. The antibody therapy is a
 combination of two monoclonal antibodies that is designed specifically to block infectivity
 of SARS-CoV-2. Regeneron's experimental antibody treatment is still in large-scale
 clinical trials, but has been available for compassionate use, something the FDA has to
 approve on an individual basis, as it did for the President. (CNN)
- California has not seen a link between the reopening of K-12 schools for in-person learning and increased coronavirus transmission, the state's top public health official, Dr. Mark Ghaly, said Tuesday. It can take time for trends to emerge, but so far, the results are encouraging. (KABC-TV)
- America's economic rebound might falter without further financial aid from the federal government, Fed Chair Jerome Powell warned Tuesday. Too little support would lead to a weak recovery, exacerbating existing inequalities, as reported by CBS News.
 Meanwhile, President Trump halted negotiations for a new stimulus package until after the elections. (CNN)
- The race for a COVID-19 vaccine slowed Tuesday, as the FDA released strengthened rules for authorizing any COVID-19 vaccine on an emergency basis. The co-chair of Operation Warp Speed, Moncef Slaoui, revealed that the government's vaccine fast-tracking effort has urged manufacturers not to apply for emergency use authorization until they have significant amounts of vaccines to deploy. This could push back even the first such authorization expected to be for a vaccine being made by Pfizer and BioNTech, if it proves to be effective into sometime in mid- to late November. (STAT)

Latest Research News

 An experimental study demonstrates SARS-CoV-2 can remain infectious on surfaces for significantly longer time than generally considered possible. A viable virus can survive on common surfaces such as glass, stainless steel and both paper and polymer banknotes for up to 28 days at 20 degrees Celsius. On some at 40 degree Celsius,

- however, infectious virus survived less than 24 hours. (Shane Riddell et al. Virology Journal)
- South Korean drugmaker Celltrion has received regulatory approval for Phase 3 clinical trials of an experimental COVID-19 treatment. The approval comes as the company plans to seek conditional approval for its antibody drug, CT-P59, for emergency use by the end of this year. (Reuters)
- A genetic analysis of 192 coronavirus patients shows that during the early months of the pandemic, SARS-CoV-2 virus was introduced to Southern California from New York state via Europe, not directly from China. (Wenjuan Zhang et al. JAMA Infectious Diseases)
- A household survey of private households in the UK, excluding people living in care homes, other communal establishments and hospitals, shows that 76.5 percent who tested positive for SARS-CoV-2 reported no symptoms, and 86.1 percent reported none of the symptoms specific to COVID-19 such as cough, and/or fever, and/or loss of taste/smell. A more widespread testing program is necessary to capture "silent" transmission and potentially prevent and reduce future outbreaks. (Irene Petersen and Andrew Phillips Clinical Epidemiology)
- Results of a randomized trial assessing lopinavir-ritonavir treatment for COVID-19 show
 that this combination of antiviral drugs is not effective and not associated with reductions
 in 28-day mortality, duration of hospital stay, or risk of progressing to invasive
 mechanical ventilation or death. (RECOVERY Collaborative Group The Lancet)
- A study of 509 hospitalized patients in Chicago, Illinois, shows that the most frequent neurologic manifestations of SARS-CoV-2 infection were myalgias, headaches, encephalopathy, and dizziness. Encephalopathy was associated with increased morbidity and mortality, independent of respiratory disease severity. Independent risk factors for developing any neurologic manifestation were severe COVID-19 and younger age. (Eric M. Liotta et al. Annals of Clinical and Translational Neurology)

Useful Links

Urban Institute Mapping Neighborhoods Where Low-income Renters Face Greater Risks of Housing Instability and Homelessness to Inform an Equitable COVID-19 Response

The COVID Tracking Project

Protect Public Data Hub by the U.S. Department of Health and Human Services

Contact Tracing Workforce Estimator by Fitzhugh Mullan Institute for Health Workforce Equity, the George Washington University

California COVID-19 statistics by county

Los Alamos National Laboratory COVID-19 Forecasts

Paul Bogaardt et al. IPRC Working Paper

CDC Provisional Death Counts for COVID-19: Data Updates by Select Demographic and Geographic Characteristics

NBER Working papers on COVID-19 and Economics

Census COVID-19 Impact Report

CDC COVID-19 Forecasts

Johns Hopkins University CSSE international map

RAND State Policy Evaluation Tool: The Health and Economic Impacts of COVID-19 Interventions

Map of California Counties advancing to Stage 2 of reopening

Google COVID-19 Community Mobility Reports

COVID-19 Projections by the Institute for Health Metrics and Evaluation

COVID-19 Projections by the University of Texas COVID-19 Modeling Consortium

Our World in Data COVID-19 Statistics and Research

Estimation of COVID-19 epidemic evaluation by the SIR model by Milan Batista (2020), fitVirusCOVID19

Imperial College London COVID-19 Behavior Tracker

Penn Wharton Budget Model

Kaiser Family Foundation Data Tool

RAND Tool for Estimating Critical Care Capacity

NBER Working papers on COVID-19 and Economics

Becker Friedman Institute for Economics Working Papers on COVID-19

COVID-19 Research and Information from Human Capital and Economic Opportunity Global Working Group, University of Chicago

The Trump Administration's Guidelines for Opening Up America Again